India Pharma Outlook Team | Friday, 03 July 2026
The Hyderabad Pharma Firm, Shantha Biologics, has secured a major manufacturing agreement with Novo Nordisk, marking another milestone for India's pharmaceutical sector.
Under the partnership, Shantha Biologics will manufacture injectable drug cartridges for the Danish drug maker at its Hyderabad facility. The Hyderabad Pharma Firm will provide cartridge fill-finish manufacturing services, helping Novo Nordisk strengthen its global production network for injectable medicines used to treat diabetes and obesity.
The agreement highlights India's growing importance as a global manufacturing hub for advanced pharmaceutical products. While both companies have confirmed the partnership, they have not disclosed the financial details or the expected production volumes.
As part of the deal, Shantha Biologics, a part of Sanofi, will manufacture injectable drug cartridges at its US FDA-approved facility in Hyderabad. The plant specializes in sterile injectable manufacturing and has the capability to handle complex fill-finish processes that require strict quality standards.
These cartridges are commonly used in injection pens designed for medicines that treat chronic conditions such as diabetes and obesity. Although Novo Nordisk did not name any specific products, the company is known globally for its injectable therapies in these segments.
The partnership is expected to support Novo Nordisk's growing demand for reliable manufacturing capacity as the use of injectable treatments continues to rise across global markets.
Also Read: How Digital Maturity is Powering Pharma's GMP Evolution
The agreement is another example of multinational pharmaceutical companies expanding their manufacturing partnerships in India.
Key highlights of the deal include:
The deal also reflects the confidence global pharmaceutical companies have in India's ability to manufacture complex healthcare products while maintaining international quality standards.
For Novo Nordisk, the agreement helps diversify and strengthen its manufacturing network at a time when demand for injectable medicines continues to increase worldwide. Expanding production through trusted partners also helps improve supply chain flexibility.
For Shantha Biologics, the partnership enhances its position as a contract manufacturing partner for global pharmaceutical companies. The company has continued to build expertise in sterile injectables, making it well placed to support international healthcare manufacturers.
Industry experts believe such collaborations will further strengthen India's reputation as a preferred destination for pharmaceutical manufacturing. As more companies look to expand production outside their home markets, Indian facilities with proven regulatory compliance and advanced manufacturing capabilities are expected to benefit.
Novo Nordisk is a Denmark-based global pharmaceutical company focused on diabetes, obesity, and other serious chronic diseases. It is one of the world's leading manufacturers of insulin and GLP-1-based therapies, with operations in more than 170 countries.
Shantha Biologics, a part of Sanofi, is a Hyderabad-based biotechnology company known for developing and manufacturing vaccines and biologics. The company operates internationally approved manufacturing facilities and provides advanced pharmaceutical manufacturing services for global healthcare companies.
.jpg)
